13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001931118
Total reported value
$158.4M
$158.4M
35 檔
19.2%
According to the latest 13F quarterly dataset, Superstring Capital Management LP managed an equity portfolio of $158.4M at the end of Q3 2025, spanning 35 distinct U.S. exchange-listed positions.
Superstring Capital Management LP executed strategic sector rebalancing during Q3 2025, establishing 20 new positions while fully exiting 19 holdings and trimming 8 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 6.70% | -1.84% | +48.73% | |
| 2 | CDTX | Cidara Therapeutics Inc | Stock-Other | 6.46% | — | — | |
| 3 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 5.84% | — | -38.63% | |
| 4 | ETNBGBP | 89bio Inc | Stock-Other | 5.57% | — | +81.12% | |
| 5 | IMVT | Immunovant Inc | Stock-Other | 5.42% | -1.28% | — | |
| 6 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 5.31% | — | -7.29% | |
| 7 | COGT | Cogent Biosciences Inc | Stock-Other | 5.11% | +2.20% | -62.47% | |
| 8 | SVRA | Savara Inc | Stock-Other | 4.60% | -2.39% | +17.38% | |
| 9 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 4.54% | — | -8.38% | |
| 10 | SMMT | Summit Therapeutics Inc | Stock-Other | 4.01% | -12.09% | EXIT | |
| 11 | IQV | Iqvia Holdings Inc | Stock-Healthcare | 3.58% | -3.13% | EXIT | |
| 12 | CABA | Cabaletta Bio Inc | Stock-Other | 3.56% | +0.15% | +45.60% | |
| 13 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 3.55% | — | — | |
| 14 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 3.22% | +0.66% | — | |
| 15 | NKTR | Nektar Therapeutics | Stock-Other | 2.87% | — | — | |
| 16 | INSM | Insmed Inc | Stock-Healthcare | 2.81% | — | +35.79% | |
| 17 | BCAX | Bicara Therapeutics Inc | Stock-Other | 2.74% | — | -7.27% | |
| 18 | AVTX | Avalo Therapeutics Inc | Stock-Other | 2.36% | — | — | |
| 19 | SNY | Sanofi-adr | Stock-Healthcare | 2.34% | — | — | |
| 20 | ZBIO | Zenas Biopharma Inc | Stock-Other | 2.11% | — | -13.39% | |
| 21 | QURE | uniQure N.V. | Stock-Other | 1.91% | — | — | |
| 22 | TECX | Tectonic Therapeutic Inc | Stock-Other | 1.84% | — | +50.88% | |
| 23 | URGN | UroGen Pharma Ltd. | Stock-Other | 1.73% | -0.53% | — | |
| 24 | TARA | Protara Therapeutic Inc | Stock-Other | 1.54% | -0.16% | — | |
| 25 | KROS | Keros Therapeutics Inc | Stock-Other | 1.48% | — | — | |
| 26 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.45% | — | — | |
| 27 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 1.33% | — | — | |
| 28 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.26% | -2.18% | EXIT | |
| 29 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.06% | +1.74% | -74.10% | |
| 30 | RAPT | Rapt Therapeutics Inc | Stock-Other | 0.88% | — | +32.32% | |
| 31 | VIR | Vir Biotechnology Inc | Stock-Other | 0.85% | +0.81% | — | |
| 32 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.72% | — | — | |
| 33 | NBP | Novabridge Biosciences | Stock-Other | 0.52% | — | — | |
| 34 | BMEA | Biomea Fusion Inc | Stock-Other | 0.50% | -0.22% | — | |
| 35 | IPSC | Century Therapeutics Inc | Stock-Other | 0.23% | -0.19% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ETNBGBP | 89bio Inc | +4.6% | +81.12% | Add |
| 2 | CABA | Cabaletta Bio Inc | +2.8% | +45.60% | Add |
| 3 | SVRA | Savara Inc | +1.4% | +17.38% | Add |
| 4 | 430 | Terns Pharmaceuticals Inc | +1.4% | -38.63% | Trim |
| 5 | ZBIO | Zenas Biopharma Inc | +1.1% | -13.39% | Trim |
| 6 | SMMT | Summit Therapeutics Inc | +1% | — | Add |
| 7 | TECX | Tectonic Therapeutic Inc | +0.8% | +50.88% | Add |
| 8 | IPSC | Century Therapeutics Inc | 0% | — | Unchanged |
| 9 | TARA | Protara Therapeutic Inc | -0.3% | — | Unchanged |
| 10 | COGT | Cogent Biosciences Inc | -0.4% | -62.47% | Trim |
| 11 | BBIO | Bridgebio Pharma Inc | -3% | -8.38% | Trim |
| 12 | TVTX | Travere Therapeutics Inc | -3.8% | -80.60% | Trim |
| 13 | URGN | UroGen Pharma Ltd. | -3.8% | — | Trim |
| 14 | ORIC | Oric Pharmaceuticals Inc | -4.4% | -74.10% | Trim |
| 15 | ZLAB | Zai Lab Ltd-adr | -6% | +48.73% | Trim |
| 16 | CDTX | Cidara Therapeutics Inc | — | NEW | New buy |
| 17 | VRNA | Verona Pharma PLC - Adr | — | EXIT | Sold out |
| 18 | IMVT | Immunovant Inc | — | NEW | New buy |
| 19 | LEGN | Legend Biotech Corp-adr | — | EXIT | Sold out |
| 20 | JAZZ | Jazz Pharmaceuticals plc | — | NEW | New buy |
| 21 | PFE | Pfizer Inc | — | EXIT | Sold out |
| 22 | IQV | Iqvia Holdings Inc | — | NEW | New buy |
| 23 | REGN | Regeneron Pharmaceuticals | — | NEW | New buy |
| 24 | DRUG | Bright Minds Biosciences Inc | — | NEW | New buy |
| 25 | CYTK | Cytokinetics Inc | — | EXIT | Sold out |
| 26 | NKTR | Nektar Therapeutics | — | NEW | New buy |
| 27 | INSM | Insmed Inc | — | NEW | New buy |
| 28 | BCAX | Bicara Therapeutics Inc | — | NEW | New buy |
| 29 | SWTXUSD | Springworks Therapeutics Inc | — | EXIT | Sold out |
| 30 | AVTX | Avalo Therapeutics Inc | — | NEW | New buy |
| 31 | SNY | Sanofi-adr | — | NEW | New buy |
| 32 | CAPR | Capricor Therapeutics Inc | — | EXIT | Sold out |
| 33 | VSTM | Verastem Inc | — | EXIT | Sold out |
| 34 | QURE | uniQure N.V. | — | NEW | New buy |
| 35 | KROS | Keros Therapeutics Inc | — | NEW | New buy |
| 36 | SRRK | Scholar Rock Holding CORP | — | NEW | New buy |
| 37 | CRNX | Crinetics Pharmaceuticals In | — | EXIT | Sold out |
| 38 | SLNOEUR | Soleno Therapeutics Inc | — | EXIT | Sold out |
| 39 | PTGX | Protagonist Therapeutics Inc | — | NEW | New buy |
| 40 | MDGL | Madrigal Pharmaceuticals Inc | — | EXIT | Sold out |
| 41 | MLTX | Moonlake Immunotherapeutics | — | EXIT | Sold out |
| 42 | TSHA | Taysha Gene Therapies Inc | — | EXIT | Sold out |
| 43 | RAPT | Rapt Therapeutics Inc | — | NEW | New buy |
| 44 | VIR | Vir Biotechnology Inc | — | NEW | New buy |
| 45 | CRBP | Corbus Pharmaceuticals Holdi | — | NEW | New buy |
| 46 | RNAGBP | Avidity Biosciences Inc | — | EXIT | Sold out |
| 47 | NBP | Novabridge Biosciences | — | NEW | New buy |
| 48 | BMEA | Biomea Fusion Inc | — | NEW | New buy |
| 49 | PCVX | Vaxcyte Inc | — | EXIT | Sold out |
| 50 | KYTX | Kyverna Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Superstring Capital Management LP reported a total U.S. public equity portfolio value of $158.4M across 35 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ZLAB, CDTX, 430) accounted for 19.2% of total reported equity market value during Q3 2025.
Top New Position Initiated
CDTX
市值: $6.6M
Top Position Liquidated / Trimmed
VRNA
前期市值: $6.1M
During Q3 2025, Superstring Capital Management LP's top holdings by market value included ZLAB (6.7%)、CDTX (6.5%)、430 (5.8%). The largest single position, ZLAB, represented 6.7% of total portfolio value.
In Q3 2025, Superstring Capital Management LP made 52 total portfolio adjustments, initiating 20 new buys, adding to 5 positions, trimming 8 holdings, and fully liquidating 19 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.